Icaritin - Shenogen Pharma

Drug Profile

Icaritin - Shenogen Pharma

Alternative Names: IC-162; SNG 162

Latest Information Update: 15 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shenogen Pharma
  • Developer Chinese Academy of Medical Sciences; Shenogen Pharma
  • Class Antineoplastics; Benzopyrans; Flavonoids; Phenyl ethers; Small molecules
  • Mechanism of Action Estrogen receptor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Phase I Solid tumours
  • No development reported Breast cancer

Most Recent Events

  • 01 Jun 2018 Efficacy and adverse events data from a phase II trial in Hepatocellular carcinoma presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 20 Nov 2017 Phase-III clinical trials in Hepatocellular carcinoma (Late-stage disease) in China (PO)
  • 21 Aug 2017 Shenogen Pharma initiates a phase I clinical trial in Healthy volunteers in China (ChiCTR-OIC17012454)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top